Osteoporosis Treatment Guidelines

Introduction to Osteoporosis Treatment

• The American College of Physicians recommends bisphosphonates as the first-line pharmacologic treatment for osteoporosis in both postmenopausal women and men 1, 2

Treatment Algorithm

• Ensure adequate calcium and vitamin D intake, with 1,200 mg calcium and 600 IU vitamin D daily for ages 51-70, and 1,200 mg calcium and 800 IU vitamin D daily for ages 71+, targeting a serum vitamin D level of at least 20 ng/mL 3, 4, 5
• Recommend lifestyle modifications, including smoking cessation, limiting alcohol consumption, and fall prevention strategies 3, 5

Pharmacologic Treatment

• Bisphosphonates are the recommended first-line therapy, with options including alendronate, risedronate, and zoledronic acid, selected based on patient preference and potential side effects 1, 2, 3, 6
• Denosumab is recommended as a second-line therapy if bisphosphonates are contraindicated or not tolerated 1, 2, 4

Special Populations

• For younger postmenopausal women, consider raloxifene as an alternative first-line option 3, 5
• For patients with very high fracture risk, consider anabolic agents followed by an antiresorptive agent 1, 2

Evidence Strength and Considerations

• High-quality evidence supports bisphosphonate use in postmenopausal women, reducing hip fractures, clinical vertebral fractures, any clinical fracture, and radiographic vertebral fractures 7
• Lower-quality evidence supports bisphosphonate use in men, primarily extrapolated from studies in women 4, 8
• Bisphosphonates are cost-effective with generic formulations available 7

Important Considerations

• Consider stopping bisphosphonate treatment after 5 years unless there's a strong indication for continuation 4, 8
• Monitor for potential adverse effects, including osteonecrosis of the jaw, atypical femoral fractures, and esophageal irritation 1, 7
• For patients initially treated with anabolic agents, prescribe an antiresorptive agent after discontinuation to preserve bone density gains 4, 8

Diagnosis and Screening

• Ensure DEXA screening for all women ≥65 years and younger postmenopausal women with risk factors 3